<DOC>
	<DOCNO>NCT01465230</DOCNO>
	<brief_summary>This study determine whether Lenalidomide improve effectiveness treatment chronic lymphocytic leukemia follow chemotherapy two drug commonly use treat disease ( bendamustine rituximab ) .</brief_summary>
	<brief_title>Maintenance Therapy : Lenalidomide Following Bendamustine Rituximab Induction Therapy Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Previous induction treatment bendamustine rituximab 18 year age chronic lymphocytic leukemia ECOG performance status less equal 2 Absolute neutrophile count 1,000 Platelet count 70,000 Serious medical condition would prevent treatment lenalidomide Evidence tumor lysis syndrome Any prior treatment lenalidomide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>maintenance therapy</keyword>
</DOC>